Conversely, although our analysis currently excludes a correlation between MAPK15 expression and clinical outcome of SHH-driven MBs (Figure S5), the role of this kinase in cilia formation and, consequently, in the activation of cilia-dependent pathways such as HH but also PDGFRα or WNT, may be more rapidly challenged, at least in preclinical studies, by using already available pharmacological inhibitors for this kinase. The gene discussed is SHH; the disease is Mobius syndrome.